Heparegenix
HepaRegeniX is developing drugs for treating acute and chronic liver diseases.
Heparegenix has raised €11M across 1 funding round, most recently a Series B round in Jan 2020. Based in Ulm, Germany; founded 2015; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€11M
€11,000,000
Funding rounds
1
Investors
0
distinct backers
Active since
2020-01
latest 2020-01
Funding by year
EUR raised per yearHeparegenix — funding by year — interactive chart.
Data table
| Heparegenix — funding by year | |
|---|---|
| 2020 | €11M |
Signals
Medium confidenceRaise-next likelihood10
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-01-21 | Series B | €11M | — | View deal → |
Related news
Similar companies
same sector or country- Delivery Hero€7.1BGermany · E-commerce
- Enpal€4.6BGermany · Cleantech
- Auxmoney€3.5BGermany · Fintech
- Helsing€2.9BGermany · AI
- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
Global coverage: FundingData